At Quantivis, experience isn’t just a credential; it is the foundation of the value we deliver.
Our founder, Sandra A.G. Visser, PhD, is a recognized global thought leader for Model-Informed Drug Discovery and Development, Clinical Pharmacology and Translational Science.
She has 25 years of leadership experience across global pharmaceutical and biotechnology R&D, uniting strategic vision with efficient execution.
Leadership
We have built, scaled, and led high-performing, cross-functional and matrixed teams, managed multi-million-dollar budgets, and overseen complex vendor and CRO ecosystems. Through senior leadership roles in large pharma and innovative biotech, we have shaped development and portfolio strategies, supported board-level investment decisions, and guided multiple programs from preclinical development through global regulatory submissions and approvals. This integrated managerial and strategic leadership experience enables us to deliver pragmatic, decision-focused solutions that reduce risk, accelerate development, and create durable value for organizations and patients.
Therapeutic Breadth
Our expertise spans a range of therapy areas including oncology, neuroscience, metabolic, renal, respiratory, immunology, hematological, and rare diseases, and a broad range of therapeutic modalities including small molecules, biologics, ADCs, RNA therapeutics, peptides, and protein degraders.
Strategic Impact
We bring extensive experience in the application of a data-driven decision-making approach that integrates pharmacology, quantitative modeling, and translational insights to reduce uncertainty and improve development outcomes. By informing dose selection, optimizing trial design, and strengthening go/no-go decisions, we have helped teams accelerate portfolio progress with greater confidence.
In parallel, we have delivered robust, decision-ready evidence packages by clearly articulating scientific and strategic value that support investor engagement, fundraising, and business development.
Regulatory Success
We bring extensive enterprise level governance and regulatory experience with a track record of successful INDs, NDAs, BLAs, and MAAs across North America, Europe and Asia.
Why It Matters
This experience matters because it enables us to spot value-creating opportunities quickly and execute with confidence. We know where quantitative insight can inform decisions, and how to deliver that insight within the regulatory, organizational, and investor constraints. For clients, this means pragmatic, decision-focused efforts where they can have the greatest impact.